Filing Details

Accession Number:
0001181431-13-038199
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-07-02 17:56:20
Reporting Period:
2013-06-28
Filing Date:
2013-07-02
Accepted Time:
2013-07-02 17:56:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1396814 Pacira Pharmaceuticals Inc. PCRX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1383242 S James Scibetta C/O Pacira Pharmaceuticals, Inc.
5 Sylvan Way, Suite 100
Parsippany NJ 07054
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-06-28 10,000 $1.61 15,000 No 4 M Direct
Common Stock Disposition 2013-06-28 10,000 $28.05 5,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2013-06-28 10,000 $0.00 10,000 $1.61
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
52,989 2020-09-02 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.12, inclusive. The reporting person undertakes to provide to Pacira Pharmaceuticals, Inc., any security holder of Pacira Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4.
  3. The option vested as to 25% of the option shares on September 2, 2011 and vests as to the remaining shares in successive equal monthly installments for the subsequent 36 months. The option shares became exercisable, to the extent vested, from and after the Issuer's initial public offering.